Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

May-Britt Tessem

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|November 7, 2016
A PET/MRI study towards finding the optimal [<sup>18</sup>F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancerMattijs Elschot, Kirsten M Selnæs, Elise Sandsmark, et al.
Gigascience|May 14, 2025
Spatial integration of multi-omics data from serial sections using the novel Multi-Omics Imaging Integration ToolsetMaximilian Wess, Maria K Andersen, Elise Midtbust, et al.
Investigative Radiology|September 27, 2012
Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathologyKirsten M Selnæs, Arend Heerschap, Line R Jensen, et al.
Plos One|April 30, 2013
Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressivenessGuro F Giskeødegård, Helena Bertilsson, Kirsten M Selnæs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2017
Combined <sup>18</sup>F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate CancerMattijs Elschot, Kirsten M Selnæs, Elise Sandsmark, et al.
British Journal of Cancer|December 4, 2015
Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasiaGuro F Giskeødegård, Ailin Falkmo Hansen, Helena Bertilsson, et al.
Biopreservation and Biobanking|April 10, 2025
Biobanking after Radical Prostatectomy: Comparison of Slice and Punch ProtocolsAnders Blilie, Guro F Giskeødegård, Åsmund Nybøen, et al.
NMR in Biomedicine|January 15, 2022
Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapyAilin Falkmo Hansen, Therese Stork Høiem, Kirsten Margrete Selnaes, et al.
Oncotarget|June 9, 2016
Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancerAilin Falkmo Hansen, Elise Sandsmark, Morten Beck Rye, et al.
Oncotarget|December 29, 2016
A novel non-canonical Wnt signature for prostate cancer aggressivenessElise Sandsmark, Ailin Falkmo Hansen, Kirsten M Selnæs, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
European Journal of Nuclear Medicine and Molecular Imaging|November 7, 2016
A PET/MRI study towards finding the optimal [<sup>18</sup>F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancerMattijs Elschot, Kirsten M Selnæs, Elise Sandsmark, et al.
Gigascience|May 14, 2025
Spatial integration of multi-omics data from serial sections using the novel Multi-Omics Imaging Integration ToolsetMaximilian Wess, Maria K Andersen, Elise Midtbust, et al.
Investigative Radiology|September 27, 2012
Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathologyKirsten M Selnæs, Arend Heerschap, Line R Jensen, et al.
Plos One|April 30, 2013
Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressivenessGuro F Giskeødegård, Helena Bertilsson, Kirsten M Selnæs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2017
Combined <sup>18</sup>F-Fluciclovine PET/MRI Shows Potential for Detection and Characterization of High-Risk Prostate CancerMattijs Elschot, Kirsten M Selnæs, Elise Sandsmark, et al.
British Journal of Cancer|December 4, 2015
Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasiaGuro F Giskeødegård, Ailin Falkmo Hansen, Helena Bertilsson, et al.
Biopreservation and Biobanking|April 10, 2025
Biobanking after Radical Prostatectomy: Comparison of Slice and Punch ProtocolsAnders Blilie, Guro F Giskeødegård, Åsmund Nybøen, et al.
NMR in Biomedicine|January 15, 2022
Prediction of recurrence from metabolites and expression of TOP2A and EZH2 in prostate cancer patients treated with radiotherapyAilin Falkmo Hansen, Therese Stork Høiem, Kirsten Margrete Selnaes, et al.
Oncotarget|June 9, 2016
Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancerAilin Falkmo Hansen, Elise Sandsmark, Morten Beck Rye, et al.
Oncotarget|December 29, 2016
A novel non-canonical Wnt signature for prostate cancer aggressivenessElise Sandsmark, Ailin Falkmo Hansen, Kirsten M Selnæs, et al.
Pageof 6